GHRS — GH Research PLC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1855129 ·
Last close
$18.27
Market Cap
$1.25B
52W High
$31.44
52W Low
$12.04
ADV30
332,997
Next earnings
2026-11-13

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -15,352,000 -12,450,000 359,912,000 345,088,000 10,892,000
Jun 2026 0 — -19,448,000 -15,146,000 372,349,000 345,053,000 12,859,000
Mar 2026 0 — -18,748,000 -18,967,000 275,267,000 242,652,000 11,890,000
Dec 2025 0 — -16,699,000 -14,137,000 288,230,000 246,251,000 8,527,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-51,703,000
Investing CF
$33,605,000
Financing CF
$111,736,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.92
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-187,836,000
Inventory
—
Receivables
$1,295,000
ST Investments
$17,597,000
EBIT TTM
$-62,242,000
Pretax Income TTM
$-62,270,000
Interest Exp TTM
$28,000
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -60,676,000 -48,258,000 288,230,000 8,527,000 279,703,000 -43,552,000
Dec 2024 0 -50,246,000 -38,961,000 188,273,000 9,322,000 178,951,000 -42,285,000
Dec 2023 0 -41,221,000 -35,587,000 226,300,000 7,332,000 218,968,000 -33,336,000
Dec 2022 0 -30,675,000 -22,456,000 254,362,000 4,546,000 249,816,000 -26,199,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.85

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $17.50 · spot: $18.25 · call volume: 36 · put volume: 6
Expected Move to 2027-01-15: ±$16.13 (88.38%) — implied range $2.12 – $34.38 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AVLN Avalyn Pharma Inc. $1.24B $27.92 —
AMPH Amphastar Pharmaceuticals, Inc. $1.24B $29.10 —
GENB Generate Biomedicines, Inc. $1.27B $9.84 —
KARD Kardigan, Inc. $1.23B $13.19 —
SLN Silence Therapeutics plc $1.23B $19.80 —

News headlines (Yahoo Finance, 1h cache)

Is GH Research (GHRS) Overvalued Even After Positive FDA Feedback?
2026-11-16 23:24 · Yahoo
GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-13 13:00 · Yahoo
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
2026-11-13 12:55 · Yahoo
GH Research (GHRS) Stock Looks Fully Priced As Book Value Questions Linger
2026-11-01 23:24 · Yahoo
Is GH Research (GHRS) Trading At A Premium To Fair Value?
2026-08-02 18:09 · Yahoo
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
2026-07-16 10:33 · Yahoo
GH Research Announces Publication of Phase 2a Postpartum Depression Results
2026-06-04 11:00 · Yahoo
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
2026-08-25 14:31 · Yahoo
GH Research (GHRS) Stock May Look Stretched As Book Value Trails Price
2026-10-18 22:07 · Yahoo
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.